RethinkPeptides
Performance & Doping Peptides

AICAR and Endurance: The Exercise-in-a-Pill Compound

14 min read|March 21, 2026

Performance & Doping Peptides

44% endurance gain

Sedentary mice given AICAR for four weeks ran 44% farther than controls, without any exercise training.

Narkar et al., Cell, 2008

Narkar et al., Cell, 2008

Molecular diagram of AICAR activating the AMPK pathway in skeletal muscle cellsView as image

In 2008, a single mouse study turned a nucleoside analog into the most talked-about compound in sports pharmacology. Researchers at the Salk Institute reported that AICAR, injected daily into sedentary mice for four weeks, increased running endurance by 44% without any exercise training (Narkar et al., Cell, 2008). Within months, the French anti-doping agency flagged it as a potential threat to cycling, and by 2011, WADA added AICAR to its prohibited list. The compound became known as "exercise in a pill." The reality is more complicated. AICAR is not a peptide in the strict biochemical sense. It is a nucleoside analog that activates AMP-activated protein kinase (AMPK), a cellular energy sensor. Its relevance to peptide research lies in its intersection with endogenous exercise-mimetic peptides like MOTS-c and its role in the broader story of performance-enhancing compounds in sport.

Key Takeaways

  • AICAR increased running endurance by 44% in sedentary mice by activating AMPK and inducing oxidative muscle fiber genes, without any exercise training (Narkar et al., Cell, 2008)
  • In over 4,000 cardiac surgery patients, intravenous AICAR (acadesine) at doses up to 100 mg/kg produced only mild, transient side effects comparable to placebo
  • WADA prohibited AICAR in 2011 under the Hormone and Metabolic Modulators category; it remains banned at all times, in and out of competition
  • A 2021 systematic review found that many AICAR effects previously attributed to AMPK activation are actually AMPK-independent, complicating interpretation of all prior studies
  • AICAR is not FDA-approved for any indication; a phase III cardiac ischemia trial was terminated in 2010 after interim futility analysis
  • The actual peptide exercise mimetic is MOTS-c, a mitochondrial-derived peptide that activates AMPK through a distinct mechanism and has demonstrated exercise-like metabolic effects in both animal and human studies[1]

What Is AICAR?

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside), also known as acadesine, is a nucleoside analog that occurs naturally as an intermediate in purine biosynthesis. When cells take up AICAR, it is phosphorylated to ZMP (AICA ribotide), which mimics AMP and activates AMPK.

AMPK is a master metabolic regulator. It functions as a cellular fuel gauge: when the AMP-to-ATP ratio rises (signaling energy depletion, as during exercise), AMPK activates pathways that generate ATP and suppresses pathways that consume it. This includes increasing glucose uptake, enhancing fatty acid oxidation, stimulating mitochondrial biogenesis, and promoting the expression of oxidative muscle fiber genes.

AICAR activates AMPK without actual energy depletion. It tricks the cell into responding as though it just exercised. This pharmacological shortcut is what makes AICAR interesting to exercise physiologists, and concerning to anti-doping authorities.

The 2008 Mouse Study That Changed Everything

The Narkar et al. 2008 study in Cell remains the cornerstone of AICAR's reputation. The researchers treated sedentary mice with AICAR (500 mg/kg/day, subcutaneously) for four weeks. The results:

  • Running endurance increased by 44% compared to untreated controls
  • AICAR induced expression of genes associated with oxidative (slow-twitch) muscle fibers
  • The compound activated a transcriptional program normally triggered by endurance training
  • When AICAR was combined with a PPARdelta agonist (GW1516), the effects were even more pronounced

The study also demonstrated that AICAR-treated muscles showed increased expression of PGC-1alpha, the master regulator of mitochondrial biogenesis, and shifted muscle fiber composition toward the fatigue-resistant type I profile typically seen in trained endurance athletes.

Two caveats deserve emphasis. First, the dose was enormous. Scaling 500 mg/kg from mice to humans is not straightforward, but it would correspond to tens of grams for an adult, far exceeding any dose tested in humans. Second, the mice were sedentary. The study showed that AICAR could produce exercise-like adaptations in the absence of exercise, but it did not compare AICAR to actual exercise training or test whether AICAR could enhance the adaptations produced by training.

AICAR in Humans: The Cardiac Ischemia Data

AICAR was not developed for endurance enhancement. It was developed in the 1980s as a cardioprotective agent under the name acadesine. The rationale: by activating AMPK during cardiac ischemia (when the heart is starved of blood flow), AICAR could protect cardiac tissue during surgery.

This application generated substantial human safety data:

  • Over 4,000 cardiac surgery patients received intravenous AICAR in clinical trials
  • At doses up to 100 mg/kg IV, side effects were mild and transient, comparable to placebo
  • At doses up to 210 mg/kg IV, AICAR was well tolerated
  • The main observed side effects were transient hyperuricemia (elevated uric acid) and hypoglycemia

However, the cardiac ischemia program did not succeed. A phase III trial (RED-CABG) was launched in 2009 to test whether acadesine could reduce death, stroke, or myocardial infarction after coronary artery bypass grafting. The trial was terminated in late 2010 based on an interim futility analysis, meaning the data suggested it was unlikely to show benefit even if completed.

AICAR was also tested in chronic lymphocytic leukemia (CLL). In vitro studies showed that AICAR activates AMPK and induces apoptosis in CLL cells. A phase I/II clinical trial was conducted, but AICAR has not been approved for any oncological indication.

The human data establishes that AICAR is tolerable at clinical doses, but provides no evidence for endurance enhancement in humans. No human study has tested AICAR for athletic performance.

Why WADA Banned AICAR

WADA added AICAR to the Prohibited List in 2011 under Section S4: Hormone and Metabolic Modulators. The ban applies at all times, both in and out of competition.

The prohibition was based on the Narkar 2008 mouse data and the theoretical potential for performance enhancement through AMPK activation. WADA does not require proof that a substance works in humans to ban it. Under the World Anti-Doping Code, a substance can be prohibited if it meets two of three criteria: potential to enhance performance, potential health risk to the athlete, or violation of the spirit of sport.

AICAR meets all three. The mouse endurance data suggests performance potential. The lack of human exercise studies means athletes would be experimenting on themselves. And a compound designed to produce exercise adaptations without exercise straightforwardly violates the spirit of sport.

Detection is possible. Anti-doping laboratories have developed methods to identify AICAR in urine and blood, though detection is complicated by the fact that AICAR is an endogenous metabolite. Laboratories must distinguish between natural AICAR levels and exogenous administration, typically through threshold-based or isotope ratio methods. For a broader overview of how peptide-based doping is caught, see our article on how peptide doping is detected.

The AMPK-Independent Problem

A 2021 systematic review (Visnjic et al., Cells, 2021) revealed a significant complication for interpreting all AICAR research: many effects previously attributed to AMPK activation are actually AMPK-independent.

The review documented that AICAR and its metabolite ZMP interact with multiple cellular targets beyond AMPK:

  • ZMP inhibits enzymes in purine and pyrimidine biosynthesis
  • AICAR affects inflammatory pathways through mechanisms that do not require AMPK
  • Some metabolic effects persist in AMPK-knockout models, meaning AMPK is not required
  • AICAR influences adenosine signaling, which has its own extensive downstream effects

This matters because the narrative around AICAR has been: AICAR activates AMPK, AMPK mediates exercise adaptations, therefore AICAR mimics exercise. If significant AICAR effects are AMPK-independent, then the mechanism is more complex than the "exercise in a pill" framing suggests, and the specific effects may not map cleanly onto exercise biology.

For researchers studying AMPK specifically, this means AICAR is a less clean pharmacological tool than previously assumed. For anyone interested in AICAR for its performance effects, it means the mechanism is poorly understood.

AICAR vs. MOTS-c: The Actual Peptide Exercise Mimetic

While AICAR dominated the "exercise in a pill" headlines, the actual peptide with exercise-mimetic properties is MOTS-c, a 16-amino-acid peptide encoded by mitochondrial DNA.

MOTS-c activates AMPK through a distinct mechanism. It targets skeletal muscle to enhance glucose metabolism and regulate fat metabolism.[1] In mice, MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.[2]

Critically, MOTS-c appears to be an endogenous exercise signal. Acute high-intensity exercise increases concentrations of MOTS-c in human skeletal muscle and plasma.[3] Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans.[4] MOTS-c has been characterized as an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.[5]

Exercise also modulates MOTS-c through mitohormesis, the adaptive stress response triggered by mitochondrial reactive oxygen species during physical activity.[6] A 16-week combined aerobic and resistance exercise intervention significantly increased MOTS-c levels in breast cancer survivors.[7]

The contrast is instructive. AICAR is an exogenous nucleoside that forces AMPK activation through molecular mimicry. MOTS-c is an endogenous peptide that the body produces in response to exercise and metabolic stress. Both activate AMPK, but through fundamentally different mechanisms, and MOTS-c's effects are embedded in the body's natural exercise-response circuitry. For a deeper look, see our dedicated article on MOTS-c as an exercise-mimetic peptide.

AICAR Pharmacology: Dose, Route, and Metabolism

Understanding why AICAR has not moved into human performance research requires understanding its pharmacology. AICAR is poorly bioavailable when taken orally. The cardiac surgery trials used intravenous administration, and the mouse endurance studies used subcutaneous injection. No oral formulation has demonstrated reliable AMPK activation in published research.

Once in the bloodstream, AICAR is taken up by cells via adenosine transporters and phosphorylated by adenosine kinase to form ZMP, the active AMPK-activating metabolite. ZMP accumulates intracellularly and mimics AMP binding at the gamma subunit of AMPK. The compound has a relatively short half-life, meaning sustained effects would require repeated dosing.

The mouse endurance dose (500 mg/kg/day) is informative for scale. For a 75 kg human, a direct (non-allometrically scaled) equivalent would be 37.5 grams per day. Even with allometric scaling, the dose would be in the multi-gram range. The cardiac surgery doses (up to 210 mg/kg IV) were administered as single infusions during procedures, not as chronic daily treatments. No study has administered AICAR chronically to humans to test for exercise-like adaptations.

This pharmacological profile explains why AICAR remains a research tool rather than a practical performance agent. The combination of IV-only administration, high required doses, short half-life, and AMPK-independent effects makes it an impractical candidate for exercise mimicry in humans. The interest from anti-doping agencies was warranted given the mouse data, but the practical barriers to human use are substantial.

The Limits of Exercise Mimicry

The AICAR story illustrates a broader challenge in exercise biology: exercise produces hundreds of simultaneous molecular changes across every organ system. Activating one pathway (AMPK) captures some of those changes but misses the majority.

Exercise increases brain-derived neurotrophic factor, modulates immune cell trafficking, alters the gut microbiome, reshapes the vascular endothelium, remodels bone, and triggers hormone cascades that no single pharmacological agent reproduces. Even within skeletal muscle, AMPK activation is only one of many exercise-responsive pathways. mTOR signaling, calcium/calmodulin signaling, and mechanical tension all contribute to exercise adaptations through AMPK-independent mechanisms. Weight loss from GLP-1 agonists can improve exercise capacity through reduced body mass, but that is a fundamentally different mechanism than directly activating exercise-adaptive pathways.

A peptide-based approach to exercise mimicry may ultimately involve combinations of endogenous signals rather than single agents. The mitochondrial-derived peptide family (MOTS-c, humanin, SHLP peptides) represents one class of endogenous exercise mediators. For more on humanin, which is another mitochondrial-derived peptide elevated by exercise, see our dedicated article. Researchers have also begun developing peptides that restore AMPK function in specific disease contexts, such as cancer cachexia.[8]

The appeal of "exercise in a pill" persists because millions of people cannot exercise due to disability, illness, or extreme frailty. For these populations, pharmacological exercise mimetics could be transformative. The 2024 research on AICAR preventing diabetic polyneuropathy in mice and improving mitochondrial quality in aged mouse brains suggests potential applications far beyond athletic performance. But the gap between mouse endurance data and human clinical utility remains wide.

The Bottom Line

AICAR produced striking endurance gains in sedentary mice by activating AMPK, the cellular energy sensor normally triggered by exercise. Human safety data from cardiac surgery trials shows tolerability, but no human study has tested AICAR for athletic performance. WADA banned it in 2011. A 2021 systematic review complicated the picture by showing many AICAR effects are AMPK-independent. The actual peptide exercise mimetic is MOTS-c, an endogenous mitochondrial-derived peptide that rises with exercise and activates AMPK through its own mechanism. AICAR's story is less about a drug that replaces exercise and more about how activating one node of a complex signaling network produces only a fraction of what exercise does.

Frequently Asked Questions